Howe & Rusling Inc. Buys 762 Shares of IDEXX Laboratories, Inc. $IDXX

Key Points

• Howe & Rusling Inc. increased its stake in IDEXX Laboratories, Inc. by 11.0%, acquiring an additional 762 shares, bringing their total holdings to 7,693 shares valued at approximately $3.23 million.
• IDEXX Laboratories recently reported better-than-expected quarterly earnings with an EPS of $3.63, surpassing estimates by $0.35, and has set FY 2025 guidance of 12.400-12.760 EPS.
• Major institutional investors own 87.84% of IDEXX's stock, with various hedge funds, including MorganRosel Wealth Management LLC and Migdal Insurance & Financial Holdings Ltd., adjusting their positions during the first quarter.

Howe & Rusling Inc. lifted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 11.0% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,693 shares of the company's stock after acquiring an additional 762 shares during the period. Howe & Rusling Inc.'s holdings in IDEXX Laboratories were worth $3,231,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. MorganRosel Wealth Management LLC bought a new stake in shares of IDEXX Laboratories during the first quarter valued at about $26,000. Migdal Insurance & Financial Holdings Ltd. increased its position in shares of IDEXX Laboratories by 55.6% during the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company's stock valued at $35,000 after buying an additional 30 shares during the period. WPG Advisers LLC bought a new stake in shares of IDEXX Laboratories during the first quarter valued at about $37,000. Bank of Jackson Hole Trust increased its position in shares of IDEXX Laboratories by 328.6% during the first quarter. Bank of Jackson Hole Trust now owns 90 shares of the company's stock valued at $39,000 after buying an additional 69 shares during the period. Finally, Retirement Wealth Solutions LLC increased its position in shares of IDEXX Laboratories by 40.0% during the first quarter. Retirement Wealth Solutions LLC now owns 105 shares of the company's stock valued at $44,000 after buying an additional 30 shares during the period. Hedge funds and other institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Stock Performance

NASDAQ IDXX opened at $645.16 on Friday. The company has a 50-day simple moving average of $601.69 and a two-hundred day simple moving average of $512.04. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $688.12. The firm has a market cap of $51.62 billion, a price-to-earnings ratio of 53.72, a PEG ratio of 4.13 and a beta of 1.56.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported $3.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.28 by $0.35. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The business had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.06 billion. During the same period in the prior year, the business posted $2.44 earnings per share. The company's revenue was up 10.6% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, equities analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 1,200 shares of the company's stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $656.53, for a total transaction of $787,836.00. Following the completion of the sale, the executive vice president directly owned 16,807 shares in the company, valued at $11,034,299.71. This represents a 6.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Michael Lane sold 8,411 shares of the company's stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $627.74, for a total transaction of $5,279,921.14. Following the sale, the executive vice president owned 7,132 shares of the company's stock, valued at approximately $4,477,041.68. The trade was a 54.11% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 54,057 shares of company stock valued at $34,293,468. 0.98% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research analysts have recently weighed in on IDXX shares. BTIG Research upped their price target on shares of IDEXX Laboratories from $545.00 to $785.00 and gave the stock a "buy" rating in a report on Tuesday, August 5th. Jefferies Financial Group started coverage on shares of IDEXX Laboratories in a report on Tuesday, July 1st. They issued a "buy" rating and a $625.00 price target on the stock. Leerink Partners upped their price target on shares of IDEXX Laboratories from $580.00 to $600.00 and gave the stock an "outperform" rating in a report on Thursday, July 17th. JPMorgan Chase & Co. upped their price target on shares of IDEXX Laboratories from $550.00 to $675.00 and gave the stock an "overweight" rating in a report on Monday, August 4th. Finally, Piper Sandler reissued a "neutral" rating and issued a $700.00 target price (up previously from $510.00) on shares of IDEXX Laboratories in a research note on Monday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $649.44.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.